Summary: Evaluated rivaroxaban versus warfarin for thromboembolism prophylaxis in patients with non-valvular atrial fibrillation. The primary composite endpoint of stroke and systemic embolization was no different in the two groups (rivaroxaban non-inferior to warfarin). There was decreased intracranial bleeding and fatal bleeding with rivaroxaban. No difference in overall major bleeding.
N Engl J Med. 2011 Sep 8;365(10):883-91.
Eponym: Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with VItamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation